Loading...
NPI 1710064811 · West Allis, WI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
A2cl Services, LLC is a clinical medical laboratory provider located in West Allis, Wisconsin. This profile covers 479 Medicare and 432 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | A2cl Services, LLC |
| Address | 8901 W Lincoln Ave |
| City | West Allis |
| State | WI |
| ZIP | 53227 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 1, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $98.7M |
| Medicare | $19M |
A2CL SERVICES, LLC reports Total Medicare revenue: $19M and Total Medicaid revenue: $98.7M, indicating a Medicaid-dominant billing footprint; Medicaid revenue is substantially larger than Medicare on the provider’s lifetime records, so analyses of provider risk, contract leverage, or utilization should prioritize Medicaid patterns. The provider has an NPI enumerated on 2006-11-01 (~20 years ago), establishing it as a long-tenured laboratory in the market.
The mix of top-revenue codes points to a high-throughput clinical laboratory operation with a heavy focus on both routine chemistry/endocrine testing and high-volume infectious disease and sexual health screening. On Medicare the leading individual codes by revenue include 80053 (164.6K claims, $1.6M revenue) and 80061 (123.2K claims, $1.6M revenue) and 84443 (82.9K claims, $1.3M revenue); on Medicaid the highest-volume items are U0003 (112.9K claims, $8.5M revenue), 87491 (179.2K claims, $6.3M revenue), and 87591 (178.8K claims, $6.3M revenue), reflecting both routine panels (CMP, lipid, TSH) and large-scale molecular/NAAT testing. This code mix suggests capabilities in automated chemistry, high-throughput molecular platforms, and population-level STI/HIV screening.
Revenue concentration is meaningful but not monopolistic: the provider’s precomputed top 3 Medicare codes account for 35.7% of its Total Medicare revenue and the precomputed top 3 Medicaid codes account for 31.4% of its Total Medicaid revenue. Those top-code shares indicate that a relatively small set of tests drives roughly one-third of revenue in each payer stream, while the remainder of revenue is distributed across a long tail of additional lab assays and services listed in the top-25.
Nationally in Medicare this entity appears as a high-volume outlier for many routine lab services: 80053 ranks #31 of 26416 providers (100th percentile; extreme outlier), 80061 ranks #29 of 21671 (100th percentile; extreme outlier), and 84443 ranks #30 of 19722 (100th percentile; extreme outlier). These rank and percentile positions characterize the provider as a major national-scale processor for several common lab panels and endocrine assays relative to peers.
Within Wisconsin Medicaid the provider is a dominant statewide performer for many high-volume tests: U0003 ranks #1 of 172 providers in-state (100th percentile; extreme outlier) with $8.5M revenue (12.7% of this provider's total Medicaid revenue), 87491 ranks #1 of 156 (100th percentile; extreme outlier) with $6.3M revenue (9.4%), and 87591 ranks #1 of 155 (100th percentile; extreme outlier) with $6.3M revenue (9.4%). These #1 in-state positions across multiple infectious-disease and STI codes indicate market leadership in Medicaid for molecular and NAAT testing.
Several individual codes are flagged as extreme statistical outliers or notably above typical volume across payers, reinforcing the provider’s atypical scale for specific assays: Medicare examples include 82306 (38.8K claims, $1.1M revenue; 100th percentile; extreme outlier) and 85025 (140.2K claims, $1.1M revenue; 100th percentile; extreme outlier), while Medicaid examples include 84443 (236.7K claims, $3.3M revenue; 100th percentile; extreme outlier) and 80053 (343.1K claims, $3.1M revenue; 100th percentile; extreme outlier). A small subset of tests (including molecular COVID testing U0003 and specialized panels like 0241U) show particularly elevated rank positions in national and state comparisons.
Operationally, the very large claim counts reported on several Medicaid codes—80053 (343.1K claims), 80061 (306.8K claims), and 85025 (301.3K claims)—together with high Medicaid revenues for high-volume molecular codes (U0003 112.9K claims, 87491 179.2K claims, 87591 178.8K claims) suggest contractual arrangements or referral volume from multiple clinicians, clinics, or public-health programs rather than a small outpatient practice testing only its own patients. The pattern is consistent with centralized specimen processing or lab network services that handle high specimen throughput.
Not all high-revenue items are uniformly extreme by every metric: a few codes appear at high percentiles but with labels of "typical, unremarkable volume" in the national context (for example U0003 on Medicare: 3.3K claims, $241.8K revenue — ranks #76 of 973 providers nationally; 92th percentile; typical, unremarkable volume), while many others are explicitly labeled "extreme outlier" or "notably above typical." This mixed signal underscores that the provider’s dominance is concentrated in specific tests and payer combinations (particularly Medicaid molecular and STI testing and Medicare routine panels).
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
479 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 164,590 | $10 | $1.6M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 123,240 | $10 | $1.6M |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 82,920 | $20 | $1.3M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 38,780 | $30 | $1.1M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 140,240 | $10 | $1.1M |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 82,790 | $10 | $745.1K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 13,970 | $40 | $558.9K |
| 83880 | The lab analyst measures the amount of natriuretic peptide, a hormone made by heart muscle cells, in the patient specimen. Blood levels of the hormone increase in patients with congestive heart… | 12,600 | $40 | $478.9K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 51,380 | $10 | $411K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 22,980 | $20 | $344.7K |
Showing 1–10 of 479
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 479 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
479 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81513 | 1 | 10 | 1,320 | $140 | $183.7K |
| 81445 | 1 | 10 | 250 | $580 | $144.1K |
| 87507 | 1 | 10 | 240 | $410 | $96.8K |
| U0003 | 1 | 10 | 430 | $70 | $61.9K |
| 0240U | 2 | 10 | 70 | $140 | $45.6K |
| 88305 | 10 | 300 | 460 | $40 | $44.8K |
| 87798 | 6 | 10 | 350 | $30 | $41.1K |
| 86832 | 1 | 10 | 170 | $290 | $40.2K |
| 86833 | 1 | 10 | 170 | $290 | $39K |
| 83970 | 1 | 20 | 70 | $40 | $37.9K |
Showing 1–10 of 479
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
432 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 112,920 | $80 | $8.5M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 179,200 | $40 | $6.3M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 178,830 | $40 | $6.3M |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 236,680 | $10 | $3.3M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 102,310 | $30 | $3.3M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 107,400 | $30 | $3.1M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 343,050 | $10 | $3.1M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 306,770 | $10 | $3.1M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 70,940 | $40 | $3.1M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 152,010 | $20 | $3M |
Showing 1–10 of 432
How this provider's Medicaid billing volume and revenue compare to other Wisconsin providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Wisconsin median
432 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 20 | 760 | $110 | $1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 20 | 20 | 340 | $90 | $462K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 1 | 10 | 250 | $80 | $304.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 170 | 720 | $70 | $272.7K |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 4 | 10 | 570 | $400 | $269.3K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 4 | 10 | 1,650 | $180 | $265K |
| 81229 | The lab analyst performs the technical lab test using comparative genomic hybridization (CGH) microarray, also referred to as chromosomal microarray (CMA) or molecular karyotype performed by… | 2 | 10 | 80 | $540 | $235.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1 | 260 | 3,590 | $20 | $232.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7 | 190 | 620 | $40 | $226.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1 | 160 | 990 | $30 | $191.8K |
Showing 1–10 of 432
Other providers in the same ZIP code as A2cl Services, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.